THE 3rd GENOPOLE INTERNATIONAL SYMPOSIUM ON BIOMANUFACTURING
30 years of therapeutic product biomanufacturing : outcomes and outlook
Tuesday, December 14th 2010

8:00 Registration
8:45 – 9:00 Opening and welcome address by Pierre Tambourin, CEO of Genopole®
INTRODUCTION 30 YEARS OF THERAPEUTIC PRODUCT BIOMANUFACTURING
Chair Didier HOCH

Sanofi-Pasteur MSD, France

9:00 William G. Whitford,

Thermo Fisher Scientific, USA

30 years of approved recombinant cell culture products

9:30 Jean-Hugues Trouvin,

EMA / Paris Descartes / APHP-AGEPS, France

Biotech-derived medicines ; the conclusions of an assessment by the European Medicines Agency and outlook

10:00 Tarkan Dogru,

Novartis Biotech, Huningue, France

Moving BioPharmOps Huningue to a multiple products facility

10:30 Rémi Gloeckler,

Transgène

From the dream to reality and from the bench to the factory : a biotech firm changes its business model

11:00-11:30 Coffee break and exhibition
11:30 Nadège Penhaleux-Halet,

Alcimed, France

Vaccine technologies : recent breakthroughs and new approaches for pandemic vaccines

12:00 Clarence Deffaud,

Biotem, France

Monoclonal antibodies for use in R&D, diagnostics and therapy : development strategies

12:30 Alain Beck,

Centre d’Immunologie Pierre Fabre, France

Development strategies and challenges for the next generation of therapeutic antibodies and derivatives

13:00 Lunch
14:15 Cédric Guillerme ,

Ministère de l’Economie, de l’Industrie et de l’Emploi

Direction Générale de Compétitivité, de l’Industrie et des Services

Presentation of the market study on French Biomanufacturing

IMPLEMENTING ALTERNATIVE EXPRESSION SYSTEMS VIA THE DEVELOPMENT OF APPROPRIATE TECHNOLOGIES ALTERNATIVE EXPRESSION SYSTEMS

First Part

Chair Michel Gigon,

Laporte Experts Conseil, Canada

Chair Jean-Loup Faulon,

ISSB (Institut de Biologie Systémique et Synthétique) , France

14:45 Patrick Hible, Senior Process Expert

Pharmaceutical & Biotechnology, Technip France

New challenges in the design and construction of an upgradeable production facility

14:45 Loïc Faye ,
Angany Genetics, France

Success Stories In Molecular Farming - From Bench To Bedside

15:15 Peter Wagner,

Cosmix Therapeutics, Germany

High Affinity Ligands (HAL), a new generation of biotherapeutics

15:15 Pr. Frédéric Bourgaud, Vice-Président

Recherche, Plant Advanced Technologies, France
_ New plant models and bioprocesses to produce recombinant therapeutical proteins and bioactive compounds

15:45 Louis Vezina, CSO,

Medicago, Canada

The VLPExpress high-throughput antigen presentation screening platform – value in novel vaccine development

15:45 Claude Gudin, Consultant Expert, France

Applications of microalgae

16:15 Carsten Müller,

m2p-labs GmbH, Allemagne

Integral solution for high throughput screening of clones and media composition in online monitored shaken microbioreactors

16:15 Gilles Marchal, President & CSO

Immunotherapix, France

Production of ITP-01, an anti-inflammatory derived by extended freeze-drying of BCG

16:45-17:15 Pause
   
BIOSIMILARS AND BIOGENERICS : THE OUTLOOK ALTERNATIVE EXPRESSION SYSTEMS

Second part

Chair To be confirmed Chair Jean-Loup Faulon,

ISSB (Institut de Biologie Systémique et Synthétique) , France

17:15 Jean-Louis Prugnaud, Chef de Service,
Hôpital Saint Antoine, Paris, France

Why do we say "biosimilars" and not "biogenerics" ?

17:15 Majid Mehtali, CSO et Managing Director,

Vivalis, France

Building on the unique biological properties of embryonic stem cells for the large-scale industrial manufacture of biological products

17:45 Gail Dutton, Writer for GEN

Genetic Engineering & Biotechnology News

The US Pathway to Biosimilars

17:45 Franck Zal, CEO & CSO,

Hemarina SA, France

HEMARINA-M101 and HEMARINA-M201, two families of hemoglobin from marine organisms for therapeutic and industrial applications

18:15 Sami N Guzder

Science & Innovation, Avesthagen, Bangalore, India

18:15 Marc Delcourt,

Global Bioenergies, France

Converting renewable resources into light olefins, the core platform molecules of the petrochemical industry

18:45 Discours de clôture

Frédéric Revah, Genethon, France